The Role of Complement Activation in IgM M-Protein-Associated Neuropathies

Area of Science:

• Neurology
• Immunology
• Clinical Research

Background:

• IgM monoclonal gammopathy-associated polyneuropathy involves progressive sensorimotor deficits and demyelination.
• Myelin-associated glycoprotein (MAG) antibodies are common, and nerve damage is linked to antibody binding and complement activation.
• Detailed studies on the relationship between anti-MAG antibodies, complement activation, and clinical presentation are lacking.

Purpose of the Study:

• To investigate the correlation between anti-MAG antibody titers, complement activation, and disease severity in IgM-associated polyneuropathy.
• To explore the role of complement activation in the pathogenesis of this condition.

Main Methods:

• Serum samples from 101 patients with IgM-associated polyneuropathy were analyzed for IgM anti-MAG titers using ELISA.
• Antibody-mediated complement deposition was assessed using both ELISA-based and cell-based assays with primate peripheral nerve slides.
• Correlations between complement activation, anti-MAG titers, and clinical characteristics were examined.

Main Results:

• IgM anti-MAG titers showed significant correlation with complement deposition in ELISA-based assays (Spearman rho 0.80; p < 0.0001).
• Complement deposition varied significantly between samples with similar anti-MAG titers and was also observed in some anti-MAG negative patients, suggesting other autoantibodies.
• Clinical characteristics of polyneuropathy did not correlate with anti-MAG titers or complement activation levels.

Conclusions:

• Anti-MAG antibody titers correlate with complement activation, but this relationship does not consistently predict clinical disease severity in IgM-associated polyneuropathy.
• The weak correlation between complement activation and clinical features suggests that complement inhibitors may not be an effective treatment strategy at this time.